A Study to Investigate OCS Tapering in Adult Participants With Generalized Myasthenia Gravis Treated With Ravulizumab

Inclusion Criteria:

• Aged greater than 18 years and male or female

• Clinical diagnosis of gMG

• Receiving ravulizumab treatment prior to enrollment

• Receipt of OCS therapy equivalent to a daily dose ≥ 7.5 mg ofprednisone/prednisolone for ≥ 4 continuous weeks directly preceding enrollment

• A participant of childbearing potential must have a negative highly sensitivepregnancy test (serum or urine, as required by local regulations) taken at Screeningbefore OCS tapering begins.

• Willing to sign informed consent

Exclusion Criteria:

• Concurrent participation in an interventional clinical trial.

• History of chronic hypoadrenalism (ie, Addison's disease).

• Use of concomitant OCS for comorbid conditions other than gMG

• Receipt of a biologic for gMG (e.g., efgartigimod, rozanolixizumab, inebilizumab,rituximab, intravenous immunoglobulin) within 5 half-lives of enrollment

• Pregnant, breastfeeding, or intending to conceive during the course of the study